The global Percutaneous Electrical Nerve Stimulators (PENS) market is set for significant expansion, projected to grow from USD 311.3 million in 2025 to USD 547 million by 2035, registering a CAGR of 5.8% during the forecast period, according to the latest market analysis.
This growth trajectory is being driven by the escalating prevalence of chronic pain and neurological disorders, coupled with the global shift toward non-invasive, opioid-free pain management therapies. Percutaneous electrical nerve stimulation is increasingly emerging as a preferred alternative to pharmacological treatments, aligning with healthcare systems’ focus on safer and more effective long-term solutions.
Key Industry Highlights and Growth Drivers
- Market Size: USD 311.3 million in 2025
- Forecast Value: USD 547 million by 2035
- Growth Rate: CAGR of 5.8%
- Leading Application: Chronic Musculoskeletal Pain (32% share)
- Top Growth Region: Asia-Pacific, led by India (10.1% CAGR)
- Major Players: IonClinics, Vertis Neurosciences, Biowave Corp., SPR Therapeutics, DyAnsys, NeurAxis
The PENS market is carving out a specialized niche, accounting for 2–3% of the global medical devices market and up to 7% in the pain management segment, as patients and clinicians increasingly prioritize non-invasive therapeutic options.
Technological innovation is playing a pivotal role in this expansion. Advanced modalities such as fine-needle electrodes for precise depth targeting, image-guided insertion, and remote programming platforms are differentiating premium suppliers. In addition, industry experts anticipate consolidation, with large medtech companies likely to acquire niche neurostimulation specialists to build integrated chronic pain portfolios.
Click Here for More Information:- https://www.futuremarketinsights.com/reports/percutaneous-electrical-nerve-stimulators-market
Regulatory and Competitive Milestones Fueling Growth
In a significant industry development, NeurAxis recently received expanded FDA 510(k) clearance for its IB-Stim device, broadening its application across multiple patient groups. This move underscores the market’s momentum toward non-opioid neuromodulation therapies, which are increasingly critical in addressing the opioid crisis.
“We are excited to receive this new 510(k) clearance for IB-Stim, which expands the IB-Stim addressable market by roughly 75%,” stated Brian Carrico, President and CEO of NeurAxis.
Meanwhile, SPR Therapeutics continues to lead with its SPRINT® PNS System, recognized for delivering lasting pain relief even post-treatment, aligning with the market’s demand for cost-effective, minimally invasive outpatient solutions.
In March 2025, Nervonik, Inc. closed a USD 13 million Series A funding round led by USA Venture Partners to accelerate the development of a next-generation wireless peripheral nerve stimulation system, further intensifying competitive innovation in this fast-evolving space.
Regional Insights: Asia-Pacific Outpaces Global Growth
The Asia-Pacific region is poised to dominate growth, with India projected to register a CAGR of 10.1%, followed by China at 8.9%. These markets are benefiting from expanded healthcare access, favorable reimbursement policies, and increased adoption of physiotherapy and outpatient pain management services.
- India: Government initiatives under Ayushman Bharat and inclusion of nerve stimulators in public tenders are widening access.
- China: Strong integration into outpatient physical medicine, coupled with local manufacturing and fast-track approvals, is fueling adoption.
In contrast, developed markets like the United States (6.3% CAGR) and Germany (5.2% CAGR) are witnessing steady growth, supported by established reimbursement frameworks and the rising preference for non-opioid pain solutions.
Get Sample Report: – https://www.futuremarketinsights.com/reports/sample/rep-gb-22424
Industry Challenges and Opportunities
While the market outlook remains positive, high device costs and the need for specialized training continue to restrict penetration in resource-limited settings. However, innovations in reusable systems, leasing models, and insurance coverage expansion are expected to mitigate these barriers.
Key growth opportunities lie in extended-wear PENS systems, Bluetooth-enabled home-use stimulators, and AI-integrated pain management platforms—technologies projected to redefine patient care in the next decade.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
